Printer Friendly

CISTRON ANNOUNCES INCREASED THIRD QUARTER EARNINGS AND SALES

 CISTRON ANNOUNCES INCREASED THIRD QUARTER EARNINGS AND SALES
 PINE BROOK, N.J., May 27 /PRNewswire/ -- Cistron Biotechnology, Inc. today reported increased earnings and sales for its third quarter ended March 31, 1992.
 Net income for the third quarter increased to $121,725 from last year's figure of $36,652. Third quarter sales were $273,428, up from $272,705 in the comparable 1991 quarter.
 Net income for the first nine months was $98,741 versus $70,681 for the same period last year. Sales were $779,440 compared with $799,204 in 1991.
 Cistron's primary product area is immune response regulators, known as lymphokines. The company manufactures and sells lymphokine assay kits to pharmaceutical companies, the government and academic institutions in the United States, Europe and the Far East for cancer, arthritis and other autoimmune disease research.
 The company is currently expanding its product line and has initiated research on IL-1 beta inhibitors. An effective inhibitor would reduce inflammation and possible bone and cartilage deterioration in such autoimmune diseases as rheumatoid arthritis and lupus.
 CISTRON BIOTECHNOLOGY, INC.
 Three months ended March 31 1992 1991
 Net sales $273,428 $272,705
 Earnings before income taxes 121,725 36,652
 Income taxes 36,434 14,730
 Extraordinary credit - tax loss
 carryforward 36,434 14,730
 Net income 121,725 36,652
 Net income (loss) per share -- --
 Weighted avg. no. of shares
 outstanding 30,560,928 25,017,191
 Nine months ended March 31 1992 1991
 Net sales 779,440 799,204
 Earnings before income taxes 98,741 70,681
 Income taxes 26,682 28,405
 Extraordinary credit - tax loss
 carryforward 26,682 28,405
 Net income (loss) 98,741 70,681
 Net income (loss) per share -- --
 Weighted average number of shares
 outstanding 27,985,833 25,017,191
 -0- 5/27/92
 /CONTACT: Harold Smith of Hal Smith Associates, 201-305-0244, for Cistron Biotechnology/ CO: Cistron Biotechnology, Inc. ST: New Jersey IN: MTC SU: ERN


AH-OS -- NY002 -- 4093 05/27/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1992
Words:331
Previous Article:ASSOCIATION'S NEW TOLL-FREE HOTLINE OFFERS ANSWERS TO SMALL BUSINESS OWNERS' QUESTIONS
Next Article:CARLTON COMMUNICATIONS ANNOUNCES INTERIM RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 1992
Topics:


Related Articles
CISTRON WILL USE EQUITY AGREEMENT PROCEEDS TO EXPAND INTERLEUKIN-1 INHIBITOR RESEARCH PROGRAM
CISTRON SUES PEPROTECH FOR INTERLEUKIN-1 PATENT INFRINGEMENT
NEW CANCER GENETHERAPY IS GOAL OF PROJECT BY CISTRON BIOTECHNOLOGY AND GENETIC THERAPY
CISTRON BIOTECHNOLOGY SUES IMMUNEX CORP. OVER INTERLEUKIN-1b PATENT
CISTRON BIOTECHNOLOGY REPORTS SALES INCREASE FOR SECOND QUARTER AND SIX MONTHS
/C O R R E C T I O N -- IMMUNEX/CISTRON/(Correction Notice)
CISTRON ANNOUNCES RESULTS FOR SECOND QUARTER
CISTRON-IMMUNEX TRIAL WILL BE RESCHEDULED TO SEPTEMBER
Cistron Biotechnology Retains BlueStone Capital Partners as Its Financial Advisor
Cistron Retains Genome Securities as its Investment Banker.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters